Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms

American Journal of Transplantation

Volumn 3, Issue 4, 2003, Pages 477-483

  Zheng, HongXia ^a   Webber, Steven ^a   Zeevi, Adriana ^a   Schuetz, Erin ^b   Zhang, Jiong ^b   Bowman, Pamela ^a   Boyle, Gerard ^a   Law, Yuk ^a   Miller, Susan ^a   Lamba, Jatinder ^b   Burckart, Gilbert J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Multidrug resistance; P glycoprotein; Polymorphism; Tacrolimus dosing; Transplantation

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; EXON; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; NUCLEOTIDE SEQUENCE; PEDIATRIC SURGERY;

BASE SEQUENCE; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 0037693831     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00077.x     Document Type: Article

References (45)

1. Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S. Tacrolimus is a class II low-solubility high-permeability drug. the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 2002; 91: 719-729.
2. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 2000; 68: 98-103.
3. Hashimoto Y, Sasa H, Shimomura M, Inui K. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res 1998; 15: 1609-1613.
4. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999; 62: 25-31.
5. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450, 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129-134.
6. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
7. Hitzl M, Drescher S, van der Kuip H et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 293-298.
8. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on doseadjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048-1052.
9. Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-174.
10. Tanabe M, leiri I, Nagata N et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137-1143.
11. Kerb R, Aynacioglu AS, Brockmoller J et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001; 1: 204-210.
12. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
13. Haehner BD, Gorski JC, Vandenbranden M et al. Bimodal distribution of renal cytochrome P450, 3A activity in humans. Mol Pharmacol 1996; 50: 52-59.
14. Zheng HWS, Zeevi A, Schuetz E et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 2002; 63: 765-770.
15. Webber SA. 15 years of pediatric heart transplantation at the University of Pittsburgh: lessons learned and future prospects. Pediatr Transplant 1997; 1: 8-21.
16. Warty V, Zuckerman S, Venkataramanan R et al. Tacrolimus analysis: a comparison of different methods and matrices. Ther Drug Monit 1995; 17: 159-167.
17. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucl Acids Res 1997; 25: 2745-2751.
18. Rieder MJ, Taylor SL, Tobe VO, Nickerson DA. Automating the identification of DNA variations using quality-based fluorescence re-sequencing: analysis of the human mitochondrial genome. Nucl Acids Res 1998; 26: 967-973.
19. Ameyaw MM, Regateiro F, Li T et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-221.
20. Mathew A, Talbot D, Minford EJ et al. Reversal of steroidresistant rejection in renal allograft recipients using FK506. Transplantation 1995; 60: 1182-1184.
21. Jordan ML, Naraghi R, Shapiro R et al. Tacrolimus rescue therapy for renal allograft rejection - five-year experience. Transplantation 1997; 63: 223-228.
22. Ellis D. Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. Pediatr Nephrol 1995; 9: 487-494.
23. Jusko WJ, Thomson AW, Fung J et al. Consensus document. therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995; 17: 606-614.
24. Venkataramanan R, Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404-430.
25. Andrews PA, Sen M, Chang RW. Racial variation in dosage requirements of tacrolimus. Lancet 1996; 348: 1446.
26. Mancinelli LM, Frassetto L, Floren LC et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24-31.
27. Woodle ES, Thistlethwaite JR, Gordon JH et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 1996; 62: 594-599.
28. Kahan BD, Welsh M, Schoenberg L et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599-606.
29. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-269.
30. Kaplan B, Lown K, Craig R et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation 1999; 67: 333-335.
31. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 1996; 93: 4001-4005.
32. Schaeffeler E, Eichelbaum M, Brinkmann U et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358: 383-384.
33. Fellay J, Marzolini C, Meaden ER et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-36.
34. Bertilsson PM, Olsson P, Magnusson KE. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells. J Pharm Sci 2001; 90: 638-646.
35. Hartmann G, Kim H, Piquette-Miller M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int Immunopharmacol 2001; 1: 189-199.
36. Lee G, Piquette-Miller M. Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol 2001; 79: 876-884.
37. Muntane-Relat J, Ourlin JC, Domergue J, Maurel P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 1995; 22: 1143-1153.
38. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199.
39. Isaacs RB, Lobo PI, Nock SL, Hanson JA, Ojo AO, Pruett TL. Racial disparities in access to simultaneous pancreas-kidney transplantation in the United States. Am J Kidney Dis 2000; 36: 526-533.
40. Ross W, Solomon H, Reese J, Fairchild R, Garvin P, Kurtz M. Beneficial effects of HLA-DR3 gene expression on renal allograft survival in black recipients. Transplant Proc 1993; 25: 2408-2410.
41. Koyama H, Cecka JM, Terasaki PI. Kidney transplants in black recipients. HLA matching and other factors affecting long-term graft survival. Transplantation 1994; 57: 1064-1068.
42. Johnson CD, Wicks MN, Milstead J, Hartwig M, Hathaway DK. Racial and gender differences in quality of life following kidney transplantation. Image J Nurs Sch 1998; 30: 125-130.
43. Gupta P, Hart J, Cronin D, Kelly S, Millis JM, Brady L. Risk factors for chronic rejection after pediatric liver transplantation. Transplantation 2001; 72: 1098-1102.
44. Nair S, Eustace J, Thuluvath PJ. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 2002; 359: 287-293.
45. Webber SA, Naftel DC, Parker J, Mulla N, Balfour I, Kirklin JK, Morrow WR. Late rejection episodes greater than 1 year after pediatric heart transplantation, risk factors and outcomes. J Heart Lung Transplant 2003; in press.